Christopher Blyth
Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases; Co-Head, Infectious Diseases Epidemiology, Wesfarmers Centre of Vaccines and Infectious Diseases, Honorary and NHMRC Emerging Leadership Fellow
MBBS (Hons) DCH FRACP FRCPA PhD
christopher.blyth@uwa.edu.au
Professor Chris Blyth is a clinical academic, NHMRC Emerging Leadership Fellow and Centre Head of Wesfarmers Centre for Vaccines and Infectious Diseases, based at The Kids Research Institute Australia. He is Professor of Paediatrics with the School of Medicine, University of Western Australia, a Paediatric Infectious Diseases Physician at Perth Children's Hospital and a Clinical Microbiologist with PathWest Laboratory.
Professor Blyth has nearly two decades experience in conducting clinical paediatric and infectious diseases research focusing on questions relevant to public policy and clinical practice. The majority of his research is in influenza, vaccine-preventable respiratory tract infection, pneumonia and vaccine safety. His PhD (Preventing influenza morbidity in Australian children through vaccination; 2016) evaluated the WA preschool influenza vaccination program and has been instrumental in influencing national and state influenza policy. Professor Blyth has previously held a NHMRC Career Development Fellowship (2016-2019: Evaluation and optimisation of paediatric vaccination programs in Australia and the region) and more recently was awarded a NHMRC Emerging Leader Fellowship (2020-2024: Paediatric Acute Respiratory Infection Management & Prevention: Platforms for the Future). He is an Associate Member of the Australasian Academy of Health and Medical Science and sits on the Scientific Steering Committee of the Human Vaccines Project.
Professor Blyth co-leads the Wesfarmers Centre Infectious Disease Epidemiology team, a multidisciplinary group of researchers using administrative data, case-control and cohort studies, and clinical trials to investigate the burden of specific respiratory pathogens and identify better ways to diagnose, treatment and prevent acute respiratory infections in children. He collaborates broadly with other research groups within the Wesfarmers Centre, The Kids Research Institute Australia, Perth Children’s Hospital, other Australian paediatric tertiary hospitals and the Papua New Guinea Institute of Medical Research.
Professor Blyth was appointed as a member of the Australian Technical Advisory Group on Immunisation (ATAGI) in 2012, serving until December 2021. He was the ATAGI deputy chair from 2015, and co-chair from 2018, playing a key role in the development and implementation of Australia’s COVID-19 vaccination program. Professor Blyth was appointed to the Commonwealth Government’s COVID-19 Vaccines and Treatments for Australia Science and Industry Technical Advisory Group (SITAG) in August 2020 and, through these positions, he has been instrumental in a number of significant changes in national immunisation policy.
Projects
Estimating the Impact And Costs of Antimicrobial Resistance (AMR) at Perth Children’s Hospital
AMR is a rapidly growing challenge and has been identified as one of the World Health Organizations top 10 global health threats, with the potential to undo many of the health gains observed over the last century.
The STAMP RSV Program
STAMP-RSV is guided by a community reference group with lived experiences of RSV. The goal is to translate research findings into effective and efficient RSV control policies to reduce the health and economic burden of RSV.
July 2024
Moort Vax Waangkiny: Understanding reasons for routine vaccine uptake among Aboriginal children aged <5 years in Perth (Boorloo) metro
Aboriginal children aged younger than 5 years in Perth (Boorloo) have lower vaccine uptake compared to non-Aboriginal children.
Infection Transmission in Early Childhood Education and Care: a mixed methods study to inform future interventions
The COVID-19 pandemic has exposed many uncertainties and incorrect assumptions about respiratory pathogen transmission.
Enhancing Protection against Influenza and COVID-19 for pregnant women and medically at risk children: EPIC Study
Pregnant women are 3 times more likely to die from COVID-19 and over 7 times more likely to be admitted to an intensive care unit with influenza compared to non-pregnant women.
Patient-Reported Outcome Measures for Acute Lower Respiratory Infection (ALRI-PRO): Developing and Establishing Content Validity
Patient (or parent/carer proxy) Reported Outcomes (PROs) are those reported from a patient perspective, capturing how they feel, function, or survive.
AGAR Kids
Bacteraemia is associated with significant morbidity and mortality in children and adults, more frequently affecting neonates, Indigenous children and children admitted to hospital.
March 2023
Compound Repurposing Into Novel Therapeutics In COVID-19 At risk Lungs (CRITICAL Study)
WHO SARI & RSV Surveillance in Australia
Characterisation of invasive Group B Streptococcus in Western Australian infants over a 15-year period
Targeting interventions to improve influenza control: a proof of principle geomapping study
PATRIC: Pragmatic Adaptive Trial for Respiratory Infections in Children
Safety and Immunogenicity of Early Quadrivalent Influenza Vaccine: A phase 2prospective randomised open-label feasibility study (FluBub)
“It’s all gone quiet…” MUSIC from COVID19
September 2020
Optimising influenza vaccine uptake in children with medical comorbidities
CORONAVAX – Preparing Community and Government
Does Repeated Influenza Vaccination Constrain Influenza Immune Responses and Protection?
Sero-epidemiology of SARS-CoV-2V-2 in Western Australia
The PneuCaPTIVE study
September 2020
Pneumo-BNA: Using Bayesian network models to facilitate a microbiological diagnosis in childhood pneumonia: development of a clinical decision support tool
Linkage of the Australian Childhood Immunisation Register (ACIR) and state-based registers to evaluate and inform Australia’s immunisation program
Integrate, Identify, Intervene (Triple I Project): Identifying opportunities for preventing respiratory infections in children through integrating population-based health and laboratory data
Influenza vaccination in Western Australian children: an economic evaluation to inform future state and national programs
Determining the off-target effects of infant vaccines on respiratory infection outcomes in Western Australian children
Childhood pneumonia in the Eastern Highlands Province of Papua New Guinea: clinical, microbiological and immunological predictors of disease
FluBubs: Safety and immunogenicity of Early Quadrivalent Influenza Vaccine
Improving Health Outcomes in the Tropical North: A Multidisciplinary Collaboration (HOT NORTH)
Study of an oral medication for infants hospitalized with Respiratory Syncytial Virus (RSV) infection
PneumoWA: A case-control study of the role of viral and bacterial pathogens in causing pneumonia among Western Australian children
AusVaxSafety
August 2020
The Long-term Impact of Serogroup B Invasive Meningococcal Disease (IMD) in Australian Adolescents and Young Adults: AMEND study
Protective Vaccine Responses in Infants after Maternal Pertussis Vaccination (PRIME) Study
TESTOV Pneumo
July 2020
Prediction of Causative Pathogen of Osteomyelitis Using Bayesian Network Modelling
Defining the microbes in the middle ear and upper respiratory tract that lead to recurrent ear infections – a metagenomic study
Using the latest sequencing technology to examine the microbial composition of the middle ear & nasopharyngeal region, the site of initial colonization of OM
FluCAN - The Influenza Complications Alert Network
The main aim of the study is to provide timely surveillance data to public health authorities on severe influenza.
Paediatric Active Enhanced Diseases Surveillance (PAEDS)
PAEDS monitors for key vaccine preventable conditions and severe side effects from vaccine in 5 paediatric hospitals in Australia.
Published research
The Platform trial In COVID-19 vaccine priming and BOOsting (PICOBOO) booster vaccination substudy protocol
Coronavirus-2019 (COVID-19) vaccination in Australia commenced in February 2021. The first vaccines recommended for use were AZD1222 and BNT162b2, both delivered as a two-dose primary schedule. In the absence of sustained immunity following immunisation, recommendations for booster vaccination have followed. It is likely that periodic boosting will be necessary for at least some Australians, but it is unknown what the optimal booster vaccines and schedules are or for whom vaccination should be recommended.
Novel coenzyme Q6 genetic variant increases susceptibility to pneumococcal disease
Acute lower respiratory tract infection (ALRI) remains a major worldwide cause of childhood mortality, compelling innovation in prevention and treatment. Children in Papua New Guinea (PNG) experience profound morbidity from ALRI caused by Streptococcus pneumoniae. As a result of evolutionary divergence, the human PNG population exhibits profound genetic variation and diversity. To address unmet health needs of children in PNG, we tested whether genetic variants increased ALRI morbidity.
The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster
PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. We report data for second boosters among individuals 50-<70 years old primed with AZD1222 (50-<70y-AZD1222) until Day 84.
Characterization of Gram-negative Bloodstream Infections in Hospitalized Australian Children and Their Clinical Outcomes
Gram-negative bloodstream infections (GNBSIs) more commonly occur in children with comorbidities and are increasingly associated with antimicrobial resistance. There are few large studies of GNBSIs in children that relate the clinical presentation, pathogen characteristics, and outcomes.
The seroprevalence of SARS-CoV-2-specific antibodies in Australian children: A crosssectional study
Following reduction of public health and social measures concurrent with SARS-CoV-2 Omicron emergence in late 2021 in Australia, COVID-19 case notification rates rose rapidly. As rates of direct viral testing and reporting dropped, true infection rates were most likely to be underestimated.
Widening the lens for pandemic preparedness: children must be seen and heard
The Australian and New Zealand Paediatric Infectious Diseases (ANZPID) Group of the Australasian Society for Infectious Diseases (ASID) calls for urgent consideration of the needs and voices of children in response to the COVID-19 pandemic, and in planning for future pandemics.
Respiratory Viral Testing Rate Patterns in Young Children Attending Tertiary Care Across Western Australia: A Population-Based Birth Cohort Study
Invasive fungal disease and antifungal prophylaxis in children with acute leukaemia: a multicentre retrospective Australian cohort study
Invasive fungal disease is a common and important complication in children with acute myeloid leukaemia (AML). We describe the epidemiology of IFD in a large multicentre cohort of children with AML.
Comorbidities and confusion: addressing COVID-19 vaccine access and information challenges
Early in the coronavirus disease 2019 (COVID-19) pandemic, evidence emerged that individuals with chronic and immunocompromising conditions faced increased risk of severe infection, including death. The Australian Government and public health authorities prioritised these citizens' access to vaccines, including them in phase 1b of the rollout from 22 March 2021.
Australian Group on Antimicrobial Research surveillance outcome programs - bloodstream infections and antimicrobial resistance patterns from patients less than 18 years of age
From 1 January 2020 to 31 December 2021, thirty-eight institutions across Australia submitted data to the Australian Group on Antimicrobial Resistance (AGAR) from patients aged < 18 years (AGAR-Kids). Over the two years, 1,679 isolates were reported from 1,611 patients. This AGAR-Kids report aims to describe the population of children and adolescents with bacteraemia reported to AGAR and the proportion of resistant isolates.
Herpes simplex virus in infancy: Evaluation of national surveillance case capture
As herpes simplex virus in infancy is not a mandatory notifiable condition in Australia, completeness of ascertainment by the Australian Paediatric Surveillance Unit (APSU) has been difficult to evaluate to date. We evaluated case capture in Queensland and Western Australia using statewide laboratory and clinical data and complementary surveillance data collected via the APSU.
Hearing loss in Australian First Nations children at 6-monthly assessments from age 12 to 36 months: Secondary outcomes from randomised controlled trials of novel pneumococcal conjugate vaccine schedules
In Australian remote communities, First Nations children with otitis media (OM)-related hearing loss are disproportionately at risk of developmental delay and poor school performance, compared to those with normal hearing. Our objective was to compare OM-related hearing loss in children randomised to one of 2 pneumococcal conjugate vaccine (PCV) formulations.
The Changing Detection Rate of Respiratory Syncytial Virus in Adults in Western Australia between 2017 and 2023
The incidence of respiratory syncytial virus (RSV) in adults is inadequately defined and the impact of SARS-CoV-2-related non-pharmaceutical interventions (NPIs) is underexplored. Using laboratory data, we described the detection rate of RSV in adults ≥16 years in Western Australia (WA) between 2017 and 2023.
Cohort profile: A population-based record linkage platform to address critical epidemiological evidence gaps in respiratory syncytial virus and other respiratory infections
The Western Australia (WA) Respiratory Infections Linked Data Platform is a population-based cohort established to investigate the epidemiology of RSV and other respiratory infections in children aged 0-10 years, incorporating microbiological testing patterns, hospital admissions, emergency department presentations, and socio-demographic data.
Changing rules, recommendations, and risks: COVID-19 vaccination decisions and emotions during pregnancy
As COVID-19 vaccinations rolled out globally from late 2020, rules and recommendations regarding vaccine use in pregnancy shifted rapidly. Pre-registration COVID-19 vaccine trials excluded those who were pregnant. Initial Australian medical advice did not routinely recommend COVID-19 vaccines in pregnancy, due to limited safety data and little perceived risk of local transmission.
Invasive fungal disease in children with solid tumors: An Australian multicenter 10-year review
Invasive fungal disease (IFD) occurs less frequently during treatment for solid compared to hematological malignancies in children, and risk groups are poorly defined. Retrospective national multicenter cohort data (2004-2013) were analyzed to document prevalence, clinical characteristics, and microbiology of IFD.
Characterization of invasive Group B Streptococcus isolates from Western Australian infants, 2004-2020
Invasive Group B Streptococcus remains a leading cause of infant morbidity and mortality. Intrapartum antibiotic prophylaxis has been implemented in many countries with a reduction in early-onset disease, but an effective vaccine may further reduce the disease burden. Candidate vaccines targeting capsular polysaccharides and surface proteins are now in clinical trials.
Influenza and pertussis vaccine coverage in pregnancy in Australia, 2016-2021
Vaccination in pregnancy is the best strategy to reduce complications from influenza or pertussis infection in infants who are too young to be protected directly from vaccination. Pregnant women are also at risk of influenza complications preventable through antenatal vaccination. Both vaccines are funded under the National Immunisation Program for pregnant women in Australia, but coverage is not routinely reported nationally.
Randomised controlled trials of behavioural nudges delivered through text messages to increase influenza and COVID-19 vaccines among pregnant women (the EPIC study): study protocol
Influenza and COVID-19 infections during pregnancy may have serious adverse consequences for women as well as their infants. However, uptake of influenza and COVID-19 vaccines during pregnancy remains suboptimal. This study aims to assess the effectiveness of a multi-component nudge intervention to improve influenza and COVID-19 vaccine uptake among pregnant women.
Nudging towards COVID-19 and influenza vaccination uptake in medically at-risk children: EPIC study protocol of randomised controlled trials in Australian paediatric outpatient clinics
Children with chronic medical diseases are at an unacceptable risk of hospitalisation and death from influenza and SARS-CoV-2 infections. Over the past two decades, behavioural scientists have learnt how to design non-coercive 'nudge' interventions to encourage positive health behaviours. Our study aims to evaluate the impact of multicomponent nudge interventions on the uptake of COVID-19 and influenza vaccines in medically at-risk children.
The effectiveness of maternal pertussis vaccination for protecting Aboriginal and Torres Strait Islander infants against infection, 2012–2017: a retrospective cohort study
To evaluate the effectiveness of maternal pertussis vaccination for preventing pertussis infections in Aboriginal and Torres Strait Islander infants under seven months of age.
Pragmatic Adaptive Trial for Respiratory Infection in Children (PATRIC) Clinical Registry protocol
Acute respiratory infections (ARI) are the most common cause of paediatric hospitalisation. There is an urgent need to address ongoing critical knowledge gaps in ARI management. The Pragmatic Adaptive Trial for Respiratory Infections in Children (PATRIC) Clinical Registry will evaluate current treatments and outcomes for ARI in a variety of paediatric patient groups.
Increase in invasive group A streptococcal disease among Australian children coinciding with northern hemisphere surges
Increases in invasive group A streptococcal disease (iGAS) have recently been reported in multiple countries in the northern hemisphere, occurring during, and outside of, typical spring peaks. We report the epidemiology of iGAS among children in Australia from 1 July 2018 to 31 December 2022.
Respiratory Syncytial Virus Reinfections in Children in Western Australia
Respiratory syncytial virus (RSV) reinfection in children is poorly understood. We examined the incidence, characteristics, and outcomes of hospital-attended RSV reinfections in children <16 years in Western Australia between 2012 and 2022.
Respiratory syncytial virus in children: epidemiology and clinical impact post-COVID-19
Respiratory syncytial virus (RSV) remains a leading cause of mortality and morbidity worldwide. RSV seasonality was disrupted by COVID-19-associated nonpharmaceutical interventions (NPIs). We review RSV seasonality, molecular epidemiology, clinical manifestations, and community awareness to inform future prevention strategies.
Superior immunogenicity of mRNA over adenoviral vectored COVID-19 vaccines reflects B cell dynamics independent of anti-vector immunity: Implications for future pandemic vaccines
Both vector and mRNA vaccines were an important part of the response to the COVID-19 pandemic and may be required in future outbreaks and pandemics. The aim of this study was to validate whether immunogenicity differs for adenoviral vectored (AdV) versus mRNA vaccines against SARS-CoV-2, and to investigate how anti-vector immunity and B cell dynamics modulate immunogenicity.
Respiratory syncytial virus in children: epidemiology and clinical impact post-COVID-19
Respiratory syncytial virus (RSV) remains a leading cause of mortality and morbidity worldwide. RSV seasonality was disrupted by COVID-19-associated nonpharmaceutical interventions (NPIs). We review RSV seasonality, molecular epidemiology, clinical manifestations, and community awareness to inform future prevention strategies.
Maternal Pertussis Vaccination, Infant Immunization, and Risk of Pertussis
Following the introduction of jurisdictional maternal pertussis vaccination programs in Australia, we estimated maternal vaccine effectiveness (VE) and whether maternal pertussis vaccination modified the effectiveness of the first 3 primary doses of pertussis-containing vaccines.
Influenza vaccination in Western Australian children: Exploring the health benefits and cost savings of increased vaccine coverage in children
To assess potential benefits and direct healthcare cost savings with expansion of an existing childhood influenza immunisation program, we developed a dynamic transmission model for the state of Western Australia, evaluating increasing coverage in children < 5 years and routinely immunising school-aged children.
West Australian parents’ views on vaccinating their children against COVID-19: a qualitative study
Australian children and adolescents were among the last local cohorts offered COVID-19 vaccines. Despite promising initial uptake, coverage subsequently plateaued, requiring further efforts to improve access and build parents’ recognition of the importance of COVID-19 vaccination.
Non-specific benefit of seasonal influenza vaccine on respiratory syncytial virus-hospitalisations in children: An instrumental variable approach using population-based data
Seasonal influenza vaccine is effective against influenza hospitalisations, but little is known about non-specific effects of the vaccine on other respiratory pathogens with similar seasonal patterns. We aimed to assess the causal impact of seasonal influenza vaccine on laboratory-confirmed hospitalisations for respiratory syncytial virus (RSV) in children using an instrumental variable strategy.
Defining the pediatric response to SARS-CoV-2 variants
The global population has been severely affected by the coronavirus disease 2019 (COVID-19) pandemic, however, with older age identified as a risk factor, children have been underprioritized. This article discusses the factors contributing to the less severe response observed in children following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including, differing viral entry receptor expression and immune responses.
Pneumococcal Conjugate Vaccines Are Protective Against Respiratory Syncytial Virus Hospitalizations in Infants: A Population-Based Observational Study
Pneumococcal conjugate vaccines (PCV) reduced the risk of respiratory syncytial virus (RSV) in a randomized clinical trial. We aimed to assess the real-world effectiveness of PCV on RSV-hospitalizations among Western Australian infants.
Inequity of antenatal influenza and pertussis vaccine coverage in Australia: the Links2HealthierBubs record linkage cohort study, 2012–2017
Pregnancy and early infancy are increased risk periods for severe adverse effects of respiratory infections. Aboriginal and/or Torres Strait Islander (respectfully referred to as First Nations) women and children in Australia bear a disproportionately higher burden of respiratory diseases compared to non-Indigenous women and infants. Influenza vaccines and whooping cough (pertussis) vaccines are recommended and free in every Australian pregnancy to combat these infections.
The Challenge of Diagnosing Invasive Pulmonary Aspergillosis in Children: A Review of Existing and Emerging Tools
Invasive pulmonary aspergillosis remains a major cause of morbidity and mortality for immunocompromised children, particularly for patients with acute leukaemia and those undergoing haematopoietic stem cell transplantation. Timely diagnosis, using a combination of computed tomography (CT) imaging and microbiological testing, is key to improve prognosis, yet there are inherent challenges in this process. For CT imaging, changes in children are generally less specific than those reported in adults and recent data are limited.
Short Message Service Reminder Nudge for Parents and Influenza Vaccination Uptake in Children and Adolescents with Special Risk Medical Conditions: The Flutext-4U Randomized Clinical Trial
Children with chronic medical conditions are at increased risk of severe influenza. Uptake of influenza vaccination in children and adolescents with these identified special risk medical conditions is suboptimal.
Modeling COVID-19 disease processes by remote elicitation of causal Bayesian networks from medical experts
COVID-19 is a new multi-organ disease causing considerable worldwide morbidity and mortality. While many recognized pathophysiological mechanisms are involved, their exact causal relationships remain opaque. Better understanding is needed for predicting their progression, targeting therapeutic approaches, and improving patient outcomes. While many mathematical causal models describe COVID-19 epidemiology, none have described its pathophysiology.
Mandating COVID-19 vaccinations for children: Attitudes of Western Australian parents
Australian governments have used vaccine mandates to drive high uptake of routine childhood vaccines and adult Coronavirus Disease 2019 (COVID-19) and influenza vaccines. We sought to understand the attitudes of Western Australian parents regarding mandating COVID-19 vaccines for children, interviewing 44 parents of children aged up to 18 years between May and December 2021. Transcripts were analysed to ascertain parents' attitudes and sources of reasoning.
Core protocol for the adaptive Platform Trial In COVID-19 Vaccine priming and BOOsting (PICOBOO)
The need for coronavirus 2019 (COVID-19) vaccination in different age groups and populations is a subject of great uncertainty and an ongoing global debate. Critical knowledge gaps regarding COVID-19 vaccination include the duration of protection offered by different priming and booster vaccination regimens in different populations, including homologous or heterologous schedules.
among children with pneumonia using a causal Bayesian network
Pneumonia remains a leading cause of hospitalization and death among young children worldwide, and the diagnostic challenge of differentiating bacterial from non-bacterial pneumonia is the main driver of antibiotic use for treating pneumonia in children. Causal Bayesian networks (BNs) serve as powerful tools for this problem as they provide clear maps of probabilistic relationships between variables and produce results in an explainable way by incorporating both domain expert knowledge and numerical data.
Acute Flaccid Paralysis in Australian Children from 2007 to 2017
Acute flaccid paralysis (AFP) surveillance continues globally as part of the World Health Organization's goal to eradicate poliomyelitis. The Australian Paediatric Surveillance Unit, Paediatric Active Enhanced Disease Surveillance network, and National Enterovirus Reference Laboratory collaborate in AFP surveillance in Australia, capturing and reviewing cases of AFP for all aetiologies in order to exclude poliovirus. We aimed to describe the AFP epidemiology in childhood over an 11 year period.
Patient-reported outcome measures for paediatric acute lower respiratory infection studies
Patient-reported outcome measures (PROMs) are recommended for capturing meaningful outcomes in clinical trials. The use of PROMs for children with acute lower respiratory infections (ALRIs) has not been systematically reported. We aimed to identify and characterise patient-reported outcomes and PROMs used in paediatric ALRI studies and summarise their measurement properties.
Off-season RSV epidemics in Australia after easing of COVID-19 restrictions
Human respiratory syncytial virus (RSV) is an important cause of acute respiratory infection with the most severe disease in the young and elderly. Non-pharmaceutical interventions and travel restrictions for controlling COVID-19 have impacted the circulation of most respiratory viruses including RSV globally, particularly in Australia, where during 2020 the normal winter epidemics were notably absent.
Timing and temporal trends of influenza and pertussis vaccinations during pregnancy in three Australian jurisdictions: The Links2HealthierBubs population-based linked cohort study, 2012–2017
Antenatal inactivated influenza and pertussis-containing vaccines offer protection against severe respiratory infections for pregnant women and infants <6 months of age. Both vaccines are recommended in pregnancy; however, little is known about temporal or jurisdictional trends and predictors of uptake.
The AuTOMATIC trial: a study protocol for a multi-arm Bayesian adaptive randomised controlled trial of text messaging to improve childhood immunisation coverage
While most Australian children are vaccinated, delays in vaccination can put them at risk from preventable infections. Widespread mobile phone ownership in Australia could allow automated short message service (SMS) reminders to be used as a low-cost strategy to effectively 'nudge' parents towards vaccinating their children on time.
Estimating the excess burden of pertussis disease in Australia within the first year of life, that might have been prevented through timely vaccination
Previous Australian studies have shown that delayed vaccination with each of the three primary doses of diphtheria-tetanus-pertussis-containing vaccines (DTP) is up to 50 % in certain subpopulations. We estimated the excess burden of pertussis that might have been prevented if (i) all primary doses and (ii) each dose was given on time.
Parents' COVID-19 vaccine intentions for children under 5 years: Brief reflections from a qualitative study
Australian authorities made COVID-19 vaccines available for children aged under 5 years old with serious comorbidities in August 2022. There is presently no universal programme for young children, but crucial to any rollout's success is whether parents are motivated and able to vaccinate. By examining parents' vaccine intentions, this study aims to inform current and future COVID-19 vaccine roll-outs for children aged under 5 years.
Australian hospital paediatricians and nurses’ perspectives and practices for influenza vaccine delivery in children with medical comorbidities
Influenza vaccination of children with medical comorbidities is critical due their increased risks for severe influenza disease. In Australia, hospitals are an avenue for influenza vaccine delivery to children with comorbidities but are not always effectively utilised. Qualitative enquiry sought to ascertainment the barriers and enablers for influenza vaccination recommendation, delivery, and recording of these children at Australian hospitals.
COVID-19 vaccine knowledge, attitudes, and experiences of health care workers in Perth, Western Australia: A qualitative study
Health care workers (HCWs) faced an increased risk of Coronavirus Disease 2019 (COVID-19). Australia’s COVID-19 vaccine rollout commenced in February 2021 to priority groups, including HCWs. Given their increased risk, as well as influence on patients’ vaccine uptake, it was important that HCWs had a positive COVID-19 vaccination experience, as well as trusting the vaccine safety and efficacy data.
The Impact of a Multifaceted Tertiary Pediatric Hospital's Antimicrobial Stewardship Service
Antimicrobials are the most commonly prescribed drug class in children. Overuse through inappropriate prescribing is a key driver of antimicrobial resistance and is recognized as one of the top 10 threats to global health by the World Health Organization.
An Unusual Resurgence of Human Metapneumovirus in Western Australia Following the Reduction of Non-Pharmaceutical Interventions to Prevent SARS-CoV-2 Transmission
Non-pharmaceutical interventions (NPIs) to reduce SARS-CoV-2 transmission disrupted respiratory virus seasonality. We examined the unusual return of human metapneumovirus (hMPV) in Western Australia following a period of absence in 2020.
ATAGI 2022 Annual Statement on Immunisation
‘Corona is coming’: COVID-19 vaccination perspectives and experiences amongst Culturally and Linguistically Diverse West Australians
Culturally and Linguistically Diverse (CALD) groups within high-income countries are at risk of being left behind by the COVID-19 vaccination rollout. They face both access and attitudinal barriers, including low trust in government and health authorities.
Protocol for establishing a core outcome set for evaluation in studies of pulmonary exacerbations in people with cystic fibrosis
Pulmonary exacerbations are associated with increased morbidity and mortality in people with cystic fibrosis (CF). There is no consensus about which outcomes should be evaluated in studies of pulmonary exacerbations or how these outcomes should be measured.
Assessing the utility of routine viral surveillance performed in children undergoing autologous stem cell transplantation at a single centre
We assessed the utility of routine viral surveillance for cytomegalovirus, Epstein–Barr virus and human adenovirus in children <16 years, undergoing autologous stem cell transplantation (ASCT) at a single centre over a 10-year period. A total of 85 ASCT were performed in 65 patients.
Urinary tract infections in children: building a causal model-based decision support tool for diagnosis with domain knowledge and prospective data
Diagnosing urinary tract infections (UTIs) in children in the emergency department (ED) is challenging due to the variable clinical presentations and difficulties in obtaining a urine sample free from contamination.
Variants of Streptococcus pneumoniae Serotype 14 from Papua New Guinea with the Potential to Be Mistyped and Escape Vaccine-Induced Protection
Streptococcus pneumoniae (the pneumococcus) is a human pathogen of global importance, classified into serotypes based on the type of capsular polysaccharide produced. Serotyping of pneumococci is essential for disease surveillance and vaccine impact measurement.
Western Australian health care workers’ views on mandatory COVID-19 vaccination for the workplace
Health care workers (HCWs) are at an increased risk of catching and spreading Coronavirus Disease 2019 (COVID-19) compared with the general community, putting health systems at risk. Several jurisdictions globally have mandated or are looking to mandate COVID-19 vaccines for this cohort, but little is known about the acceptability of this measure, especially in different contexts, and there is little qualitative data to explore nuance, depth, and the reasons behind HCWs’ opinions.
Prevalence of respiratory viruses in community-acquired pneumonia in children: a systematic review and meta-analysis
Respiratory viruses are increasingly detected in children with community-acquired pneumonia but prevalence estimates vary substantially. We aimed to systematically review and pool estimates for 22 viruses commonly associated with community-acquired pneumonia.
A quality improvement study: Optimizing pneumococcal vaccination rates in children with cochlear implants
Children with cochlear implants are at increased risk of invasive pneumococcal disease, with national and international guidelines recommending additional pneumococcal vaccines for these children. This study aimed to examine the pneumococcal immunization status and rate of invasive pneumococcal disease in children with cochlear implants at a tertiary paediatric hospital over a 12-year period.
Blinatumomab as bridging therapy in paediatric B-cell acute lymphoblastic leukaemia complicated by invasive fungal disease
Invasive fungal disease (IFD) remains a challenging complication of treatment for paediatric acute leukaemia. Consensus fungal treatment guidelines recommend withholding chemotherapy to facilitate immune recovery in this setting, yet prolonged delays in leukaemia therapy increase risk of relapse.
Unusual 2020 respiratory syncytial virus bronchiolitis season in Western Australia: Not explained by weather
To describe and explore the relationship between weather and the unusual 2020 bronchiolitis season in Western Australia during the COVID-19 pandemic.
Antifungal use in children with acute leukaemia: state of current evidence and directions for future research
Invasive fungal disease (IFD) remains a common and serious complication in children treated for leukaemia. Antifungal prescription in children with leukaemia presents unique challenges, particularly due to variation in IFD risk between and within leukaemia treatment protocols, drug toxicities and interactions between antifungals and chemotherapeutic agents.
Postinfectious Acute Cerebellar Syndromes in Children: A Nationally Ascertained Case Series From Australia 2013–2018
Postinfectious acute cerebellar syndromes show a wide spectrum of acute severity and can occur with acute febrile illness or vaccine receipt. Varicella has historically been the most common cause, associated with up to 25% of cases in large cohorts. This study aimed to describe the spectrum of syndromes in a setting with high varicella vaccine coverage.
Whole genome sequencing and molecular epidemiology of paediatric Staphylococcus aureus bacteraemia
The role Staphylococcus aureus antimicrobial resistance genes and toxins play in disease severity, management and outcome in childhood is an emerging field requiring further exploration.
Diagnosis and analysis of unexplained cases of childhood encephalitis in Australia using metatranscriptomic sequencing
Encephalitis is most often caused by a variety of infectious agents identified through diagnostic tests utilizing cerebrospinal fluid. We investigated the clinical characteristics and potential aetiological agents of unexplained encephalitis through metagenomic sequencing of residual clinical samples from multiple tissue types and independent clinical review.
Surveillance for severe influenza and COVID-19 in patients admitted to sentinel Australian hospitals in 2020: the Influenza Complications Alert Network (FluCAN)
Influenza is a common cause of acute respiratory infection, and is a major cause of morbidity and mortality. Coronavirus disease 2019 (COVID-19) is an acute respiratory infection that emerged as a pandemic worldwide before the start of the 2020 Australian influenza season.
Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2019: the Influenza Complications Alert Network (FluCAN)
This report summarises the epidemiology of hospitalisations with laboratory-confirmed influenza during the 2019 influenza season. The Influenza Complications Alert Network (FluCAN) is a sentinel hospital-based surveillance program that operates at sites in all jurisdictions in Australia.
Preventing severe influenza in Australian infants: Maternal influenza vaccine effectiveness in the PAEDS-FluCAN networks using the test-negative design
Effectiveness of 13-valent pneumococcal conjugate vaccine against hypoxic pneumonia and hospitalisation in Eastern Highlands Province, Papua New Guinea: An observational cohort study
Pneumonia is a leading cause of childhood mortality with Streptococcus pneumoniae a major contributor. Pneumococcal conjugate vaccines (PCVs) have been introduced into immunisation programs in many low- to middle-income countries yet there is a paucity of data evaluating the effectiveness in these settings. We assess the effectiveness of 13-valent PCV against hypoxic pneumonia, hospitalisation and other clinical endpoints in children <5 years living in Eastern Highlands Province, Papua New Guinea).
Rare cause of scalp swelling in an infant
Acute haemoptysis, fever and abdominal pain in an adolescent from northern Australia
Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2021
Antifungal prophylaxis can reduce morbidity and mortality from invasive fungal disease (IFD). However, its use needs to be optimised and appropriately targeted to patients at highest risk to derive the most benefit. In addition to established risks for IFD, considerable recent progress in the treatment of malignancies has resulted in the development of new 'at-risk' groups.
COVID-19 and changes in the National Immunisation Program: a unique opportunity to optimise the Australian Immunisation Register (AIR)
COVID-19 vaccination in children and adolescents aged 5 years and older undergoing treatment for cancer and non-malignant haematological conditions: Australian and New Zealand Children’s Haematology/Oncology Group consensus statement
The Australian Technical Advisory Group on Immunisation and New Zealand Ministry of Health recommend all children aged ≥ 5 years receive either of the two mRNA COVID-19 vaccines: Comirnaty (Pfizer), available in both Australia and New Zealand, or Spikevax (Moderna), available in Australia only. Both vaccines are efficacious and safe in the general population, including children. Children and adolescents undergoing treatment for cancer and immunosuppressive therapy for non-malignant haematological conditions are particularly vulnerable, with an increased risk of severe or fatal COVID-19.
Consensus guidelines for the diagnosis and management of invasive candidiasis in haematology, oncology and intensive care settings, 2021
Patients with haematological malignancies, haemopoietic stem cell transplant recipients and patients requiring admission to intensive care settings are at high risk for invasive candidiasis (IC). Over the past decade, there has been increased reporting of non-albicans species and fluconazole resistance in Australia. These guidelines provide updated evidence-based recommendations for the diagnosis and management of IC in adult and paediatric haematology, oncology and intensive care settings.
Consensus guidelines for antifungal stewardship, surveillance and infection prevention, 2021
Invasive fungal diseases (IFD) are serious infections associated with high mortality, particularly in immunocompromised patients. The prescribing of antifungal agents to prevent and treat IFD is associated with substantial economic burden on the health system, high rates of adverse drug reactions, significant drug-drug interactions and the emergence of antifungal resistance.
Olfactory dysfunction at six months after coronavirus disease 2019 infection
This study aimed to assess olfactory dysfunction in patients at six months after confirmed coronavirus disease 2019 infection. Coronavirus disease 2019 positive patients were assessed six months following diagnosis. Patient data were recoded as part of the adapted International Severe Acute Respiratory and Emerging Infection Consortium Protocol. Olfactory dysfunction was assessed using the University of Pennsylvania Smell Identification Test.
Excess respiratory mortality and hospitalizations associated with influenza in Australia, 2007-2015
Influenza is the most common vaccine-preventable disease in Australia, causing significant morbidity and mortality. We assessed the burden of influenza across all ages in terms of influenza-associated mortality and hospitalizations using national mortality, hospital-discharge and influenza surveillance data.
Pediatric Staphylococcus aureus Bacteremia: Clinical Spectrum and Predictors of Poor Outcome
Staphylococcus aureus is a common cause of bacteremia, yet the epidemiology and predictors of poor outcome remain inadequately defined in childhood. ISAIAH (Invasive Staphylococcus aureus Infections and Hospitalizations in children) is a prospective, cross-sectional study of S. aureus bacteremia in children hospitalized in Australia and New Zealand over 24 months.
Weighing the Risks of Perimyocarditis With the Benefits of SARS-CoV-2 mRNA Vaccination in Adolescents
Examining the entire delayed respiratory syncytial virus season in Western Australia
An interseasonal resurgence of respiratory syncytial virus (RSV) was observed in Western Australia at the end of 2020. Our previous report describing this resurgence compared the 2019 and 2020 calendar years, capturing only part of the 2020/21 season.
Multilocus Sequence Typing Reveals Extensive Genetic Diversity of the Emerging Fungal Pathogen Scedosporium aurantiacum
Scedosporium spp. are the second most prevalent filamentous fungi after Aspergillus spp. recovered from cystic fibrosis (CF) patients in various regions of the world. Although invasive infection is uncommon prior to lung transplantation, fungal colonization may be a risk factor for invasive disease with attendant high mortality post-transplantation. Abundant in the environment, Scedosporium aurantiacum has emerged as an important fungal pathogen in a range of clinical settings.
Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021
Invasive aspergillosis (IA) in haematology/oncology patients presents as primary infection or breakthrough infection, which can become refractory to antifungal treatment and has a high associated mortality. Other emerging patient risk groups include patients in the intensive care setting with severe respiratory viral infections, including COVID-19.
Consensus guidelines for the diagnosis and management of cryptococcosis and rare yeast infections in the haematology/oncology setting, 2021
Cryptococcosis caused by the Cryptococcus neoformans-Cryptococcus gattii complex is an important opportunistic infection in people with immunodeficiency, including in the haematology/oncology setting.
Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy and haemopoietic stem cell transplant recipients, 2021
Antifungal agents can have complex dosing and the potential for drug interaction, both of which can lead to subtherapeutic antifungal drug concentrations and poorer clinical outcomes for patients with haematological malignancy and haemopoietic stem cell transplant recipients. Antifungal agents can also be associated with significant toxicities when drug concentrations are too high.
The Interseasonal Resurgence of Respiratory Syncytial Virus in Australian Children Following the Reduction of Coronavirus Disease 2019-Related Public
Following the end of winter, there has been a persistent absence of severe acute respiratory syndrome coronavirus 2 community transmission and no increase in influenza detections. Limited physical distancing measures have remained in place, with largely no restrictions on gathering sizes and no mandate for wearing masks.
Examining the interseasonal resurgence of respiratory syncytial virus in Western Australia
Following a relative absence in winter 2020, a large resurgence of respiratory syncytial virus (RSV) detections occurred during the 2020/2021 summer in Western Australia. This seasonal shift was linked to SARS-CoV-2 public health measures. We examine the epidemiology and RSV testing of respiratory-coded admissions, and compare clinical phenotype of RSV-positive admissions between 2019 and 2020.
Introduction to the updated Australasian consensus guidelines for the management of invasive fungal disease and use of antifungal agents in the haematology/oncology setting, 2021
This article introduces the fourth update of the Australian and New Zealand consensus guidelines for the management of invasive fungal disease and use of antifungal agents in the haematology/oncology setting. These guidelines are comprised of nine articles as presented in this special issue of the Internal Medicine Journal. This introductory chapter outlines the rationale for the current update and the steps taken to ensure implementability in local settings.
Calling Future Grandparents-Further Efforts Required to Increase Human Papillomavirus Vaccination Use in Adolescence
Altered Behavior in Encephalitis: Insights From the Australian Childhood Encephalitis Study, 2013-2018
Altered mental status is a major criterion for a diagnosis of encephalitis to be made with alteration in behavior, a key manifestation of altered mental status. We reviewed all evaluated cases identified by the Australian Childhood Encephalitis study between May 2013 and June 2018.
Infectious complications and optimising infection prevention for children with cochlear implants
To describe the clinical epidemiology of children receiving cochlear implants, as well as the management and outcomes of cochlear implant infections and adherence to infection prevention measures.
Using provider-parent strategies to improve influenza vaccination in children and adolescents with special risk medical conditions: a randomised controlled trial protocol
Influenza immunisation is a highly cost-effective public health intervention. Despite a comprehensive National Immunisation Program, influenza vaccination in children and adolescents with special risk medical conditions (SRMCs) is suboptimal. Flutext-4U is an innovative, multi-component strategy targeting paediatric hospitals, general practice and parents of children and adolescents with SRMC.
Pertussis Disease and Antenatal Vaccine Effectiveness in Australian Children
Population-level studies of severe pertussis extending beyond infancy are sparse, and none in the context of antenatal vaccination. We compared hospitalized pertussis cases from birth to 15 years of age before and after introduction of antenatal immunization.
Pertussis burden and acellular pertussis vaccine effectiveness in high risk children
Pertussis hospitalisation is more common among infants born prematurely, who have significant comorbidities, or are Indigenous, but acellular pertussis (aP) vaccine effectiveness (VE) estimates in these sub-groups are lacking. We measured aP VE by Indigenous status, and policy-relevant categories of prematurity and comorbidity, in a population-based Australian cohort.
COVID-19-Related Submission Priorities From the Journal of the Pediatric Infectious Diseases Society
Preferred health outcome states following treatment for pulmonary exacerbations of cystic fibrosis
Treatment for pulmonary exacerbations of cystic fibrosis (CF) can produce a range of positive and negative outcomes. Understanding which of these outcomes are achievable and desirable to people affected by disease is critical to agreeing to goals of therapy and determining endpoints for trials.
Developing a prediction model to estimate the true burden of respiratory syncytial virus (RSV) in hospitalised children in Western Australia
Respiratory syncytial virus (RSV) is a leading cause of childhood morbidity, however there is no systematic testing in children hospitalised with respiratory symptoms. Therefore, current RSV incidence likely underestimates the true burden.
Risk factors and disease severity in Australian infants aged under 6 months hospitalised with influenza 2011–2019
Infants aged <6 months are vulnerable to severe influenza disease and no vaccine is approved for use in this age group. We aimed to describe the epidemiology, risk factors associated with severe outcomes and management of influenza in Australian infants aged <6 months.
Does a major change to a COVID-19 vaccine program alter vaccine intention? A qualitative investigation
On 8th April 2021, the Australian Technical Advisory Group on Immunisation (ATAGI) made the Pfizer-BioNtech (Comirnaty) vaccine the “preferred” vaccine for adults in Australia aged < 50 years due to a risk of thrombosis with thrombocytopenia syndrome (TTS) following AstraZeneca vaccination. We sought to understand whether this impacted COVID-19 vaccine intentions.
Consensus guidelines for improving patients' understanding of invasive fungal disease and related risk prevention in the haematology/oncology setting, 2021
Patients with invasive fungal disease (IFD) are at significant risk of morbidity and mortality. A productive partnership between patients, their carers/families, and the multidisciplinary team managing the infection and any underlying conditions, is essential.
Re-examining Hepatitis B Postexposure Prophylaxis Following Pediatric Community-acquired Needle-stick Injury in an Era of a National Immunization Registry
Long-term hepatitis B immunity has been demonstrated following the completion of the primary vaccination series in childhood. Some guidelines recommend a hepatitis B surface antibody (anti-HBs) directed approach following community-acquired needle-stick injury (CANSI) to inform hepatitis B postexposure prophylaxis (PEP) management.
ATAGI 2021 annual statement on immunisation Last updated: 19 September 2021
COVID-19 vaccine Mandates: An Australian attitudinal study
The rollout of vaccines against COVID-19 is prompting governments and the private sector to adopt mandates. However, there has been little conceptual analysis of the types of mandates available, nor empirical analysis of how the public thinks about different mandates and why. Our conceptual study examines available instruments, how they have been implemented pre-COVID, and their use for COVID-19 globally.
Interrupted time-series analysis showed unintended consequences of non-pharmaceutical interventions on paediatric hospital admissions
COVID-19-associated non-pharmaceutical interventions (NPI) have disrupted respiratory viral transmission. We quantified the changes in paediatric hospital admissions in 2020 from five different NPI phases in Western Australia for acute lower respiratory infections (ALRI) in children in the context of all-cause admissions.
Prospective characterisation of SARS-CoV-2 infections among children presenting to tertiary paediatric hospitals across Australia in 2020: A national cohort study
To present Australia-wide data on paediatric COVID-19 and multisystem inflammatory syndromes to inform health service provision and vaccination prioritisation. Design Prospective, multicentre cohort study. Setting Eight tertiary paediatric hospitals across six Australian states and territories in an established research surveillance network - Paediatric Active Enhanced Disease (PAEDS).
Influenza hospitalizations in Australian children 2010–2019: The impact of medical comorbidities on outcomes, vaccine coverage, and effectiveness
Children with comorbidities are at greater risk of severe influenza outcomes compared with healthy children. In Australia, influenza vaccination was funded for those with comorbidities from 2010 and all children aged <5 years from 2018. Influenza vaccine coverage remains inadequate in children with and without comorbidities.
Antifungal prescribing in neonates: Using national point prevalence survey data from Australia
We describe contemporary antifungal use in neonates, with point-prevalence survey data from the National Antimicrobial Prescribing Survey across Australian hospitals from 2014 to 2018.
Novel method to select meaningful outcomes for evaluation in clinical trials
A standardised framework for selecting outcomes for evaluation in trials has been proposed by the Core Outcome Measures in Effectiveness Trials working group. However, this method does not specify how to ensure that the outcomes that are selected are causally related to the disease and the health intervention being studied. Causal network diagrams may help researchers identify outcomes that are both clinically meaningful and likely to be causally dependent on the intervention, and endpoints that are, in turn, causally dependent on those outcomes.
Examining prescribing, timeliness and data recording of immunisations onto a national electronic immunisation register for inpatients at a tertiary paediatric hospital
The aim of this study was to investigate the quality and adherence of inpatient immunisation prescribing, as well as timeliness and recording of immunisations onto the national immunisation register, within a tertiary paediatric hospital setting. We conducted an observational, retrospective review of inpatient immunisations at Perth Children’s Hospital from July 2018 to February 2019.
Echinocandins in Pediatric Invasive Candidiasis and the Challenges of Antifungal Use in Children
In pediatric invasive candidiasis (IC), epidemiology and risk factors differ compared to adults. Furthermore, the use of antifungals in children is challenging and requires consideration of availability and tolerability of formulations, pharmacokinetic and pharmacodynamic variations, and safety in different age groups.
Lack of effectiveness of 13-valent pneumococcal conjugate vaccination against pneumococcal carriage density in Papua New Guinean infants
Papua New Guinea (PNG) introduced the 13-valent pneumococcal conjugate vaccine (PCV13) in 2014, with administration at 1, 2, and 3 months of age. PCV13 has reduced or eliminated carriage of vaccine types in populations with low pneumococcal carriage prevalence, carriage density and serotype diversity.
Levels of pneumococcal conjugate vaccine coverage and indirect protection against invasive pneumococcal disease and pneumonia hospitalisations in Australia: An observational study
There is limited empiric evidence on the coverage of pneumococcal conjugate vaccines (PCVs) required to generate substantial indirect protection. We investigate the association between population PCV coverage and indirect protection against invasive pneumococcal disease (IPD) and pneumonia hospitalisations among undervaccinated Australian children.
Invasive fungal disease in children with acute myeloid leukaemia: An Australian multicentre 10-year review
Invasive fungal disease (IFD) is a common and important complication in children with acute myeloid leukaemia (AML). We describe the epidemiology of IFD in a large multicentre cohort of children with AML.
The role of Kingella kingae in pre-school aged children with bone and joint infections
The Pre-school Osteoarticular Infection (POI) study aimed to describe the burden of disease, epidemiology, microbiology and treatment of acute osteoarticular infections (OAI) and the role of Kingella kingae in these infections.
Coronavax: preparing community and government for COVID-19 vaccination: a research protocol for a mixed methods social research project
Ahead of the implementation of a COVID-19 vaccination programme, the interdisciplinary Coronavax research team developed a multicomponent mixed methods project to support successful roll-out of the COVID-19 vaccine in Western Australia. This project seeks to analyse community attitudes about COVID-19 vaccination, vaccine access and information needs. We also study how government incorporates research findings into the vaccination programme.
Impact of Coronavirus Disease 2019 Public Health Measures on Detections of Influenza and Respiratory Syncytial Virus in Children During the 2020 Australian Winter
Public health measures targeting coronavirus disease 2019 have potential to impact transmission of other respiratory viruses. We found 98.0% and 99.4% reductions in respiratory syncytial virus and influenza detections, respectively, in Western Australian children through winter 2020 despite schools reopening. Border closures have likely been important in limiting external introductions.
Influenza disease and vaccination in children in Australia
Over the past decade, multiple initiatives have been implemented to strengthen influenza vaccination programs in Australia, with an increasing focus on children. In this article, we review these changes, the events that prompted them, and how they have influenced influenza vaccine uptake in Australia.
The Collaboration for Increasing Influenza Vaccination in Children (CIIVIC): a meeting report
The burden of seasonal influenza disease in Australian children is substantial, especially for those with medical comorbidities including chronic cardiac, respiratory, neurological and immunosuppressive conditions. Influenza is more likely to be severe in children with comorbidities compared to previously healthy children (e.g. more frequent and longer hospitalisation, more frequent intensive care unit admission and requiring respiratory support). Direct protection against influenza by vaccination is critical for children with comorbidities and remains the most effective tool for influenza prevention.
Clinical experience with SUBA-itraconazole at a tertiary paediatric hospital
Itraconazole remains a first-line antifungal agent for certain fungal infections in children, including allergic bronchopulmonary aspergillosis (ABPA) and sporotrichosis, but poor attainment of therapeutic drug levels is frequently observed with available oral formulations. A formulation of 'SUper BioAvailability itraconazole' (SUBA-itraconazole; Lozanoc®) has been developed, with adult studies demonstrating rapid and reliable attainment of therapeutic levels, yet paediatric data are lacking.
Barriers to influenza vaccination of children hospitalised for acute respiratory illness: A cross-sectional survey
To identify barriers to influenza vaccination of children hospitalised for acute respiratory illness in Australia. A total of 595 parents of children hospitalised with acute respiratory illness across five tertiary hospitals in 2019 participated in an online survey. Multivariate logistic regression identified factors most strongly associated with influenza vaccination barriers.
The measurement properties of tests and tools used in cystic fibrosis studies: a systematic review
There is no consensus on how best to measure responses to interventions among children and adults with cystic fibrosis (CF). We have systematically reviewed and summarised the characteristics and measurement properties of tests and tools that have been used to capture outcomes in studies among people with CF, including their reliability, validity and responsiveness. This review is intended to guide researchers when selecting tests or tools for measuring treatment effects in CF trials. A consensus set of these tests and tools could improve consistency in how outcomes are captured and thereby facilitate comparisons and synthesis of evidence across studies.
Nasopharyngeal density of respiratory viruses in childhood pneumonia in a highly vaccinated setting: findings from a case-control study
Detection of pneumonia-causing respiratory viruses in the nasopharynx of asymptomatic children has made their actual contribution to pneumonia unclear. We compared nasopharyngeal viral density between children with and without pneumonia to understand if viral density could be used to diagnose pneumonia.
Infant, maternal and demographic predictors of delayed vaccination: A population-based cohort study
Receiving vaccines at or close to their due date (vaccination timeliness) is a now key measure of program performance. However, studies comprehensively examining predictors of delayed infant vaccination are lacking. We aimed to identify predictors of short and longer-term delays in diphtheria-tetanus-pertussis (DTP) vaccination by dose number and ethnicity.
Key steps in our journey to a COVID-19 vaccine program
Providing a safe and effective coronavirus disease 2019 (COVID‐19) vaccination program is required to mitigate against the current and future negative impacts on the health and wellbeing of all Australians from COVID‐19. An effective vaccination program is a key element required to facilitate economic recovery, safe movement throughout and beyond Australia and a return to the quality of life previously experienced.
Case Report: Neonatal Varicella Acquired From Maternal Zoster
The incidence of neonatal varicella has decreased dramatically since the introduction of the varicella vaccination. Although the varicella zoster virus is often associated with a mild infection, it may cause severe morbidity and mortality, particularly in the neonatal period and immunocompromised hosts. We report a case of neonatal varicella acquired from maternal zoster in a mother on biological immunosuppressive therapy.
Improving Influenza Vaccination in Children With Comorbidities: A Systematic Review
Children with medical comorbidities are at greater risk for severe influenza and poorer clinical outcomes. Despite recommendations and funding, influenza vaccine coverage remains inadequate in these children. We aimed to systematically review literature assessing interventions targeting influenza vaccine coverage in children with comorbidities and assess the impact on influenza vaccine coverage.
Meningococcal serotype W septic arthritis: Case series in children
The epidemiology of invasive meningococcal disease has changed over the last decade and there has been an increase in cases caused by serogroup W135, particularly in Indigenous children. Extra‐meningeal and atypical presentations are associated with serogroup W and may delay diagnosis and therefore appropriate treatment. Public and clinician awareness are essential in facilitating effective new vaccine schedule implementation.
Converting the maybes: Crucial for a successful COVID-19 vaccination strategy
Broad community acceptance of a COVID-19 vaccination will be critical for effectively halting the spread of the virus. In this study, we focus on factors that differentiate those who are undecided from those who are either willing or unwilling to accept a prospective COVID-19 vaccine. An online survey in May 2020 assessed Australian adults' willingness to receive a COVID-19 vaccine (yes, maybe, no). A multinomial logistical regression of responses (N = 1,313) was used to identify correlates of vaccine willingness between the three groups.
Epidemiology and seasonality of human parainfluenza serotypes 1-3 in Australian children
Parainfluenza viruses are significant contributors to childhood respiratory illness worldwide, although detailed epidemiological studies are lacking. Few recent Australian studies have investigated serotype-specific PIV epidemiology, and there is a paucity of southern hemisphere PIV reports. We report age-stratified PIV hospitalisation rates and a mathematical model of PIV seasonality and dynamics in Western Australia (WA).
Do rapid diagnostic methods improve antibiotic prescribing in paediatric bacteraemia?
Rapid blood culture pathogen identification facilitated by matrix-assisted laser desorption ionisation time-of-flight and GeneXpert has the potential to improve antibiotic prescribing. This study investigates the impact of these rapid diagnostics on the timeliness of effective and optimal antibiotic prescribing in paediatric patients with bacteraemia.
Predictors of hospital readmission in infants less than 3 months old
To examine rates and predictors of 7-day readmission in infants hospitalised before 3 months of age with infectious and non-infectious conditions. A retrospective population-based data-linkage study of 121 854 infants from a 5-year metropolitan birth cohort (2008-2012). Cox proportional hazard models were used to examine associations between infant and maternal factors with 7-day readmission.
Outcomes and endpoints reported in studies of pulmonary exacerbations in people with cystic fibrosis: A systematic review
There is no consensus about which outcomes should be evaluated in studies of pulmonary exacerbations in people with cystic fibrosis (CF). Outcomes used for evaluation should be meaningful; that is, they should capture how people feel, function or survive and be acknowledged as important to people with CF, or should be reliable surrogates of those outcomes. We aimed to summarise the outcomes and corresponding endpoints which have been reported in studies of pulmonary exacerbations, and to identify those which are most likely to be meaningful.
Aminoglycoside use in paediatric febrile neutropenia - Outcomes from a nationwide prospective cohort study
Aminoglycosides are commonly prescribed to children with febrile neutropenia (FN) but their impact on clinical outcomes is uncertain and extent of guideline compliance is unknown. We aimed to review aminoglycoside prescription and additional antibiotic prescribing, guideline compliance and outcomes for children with FN.
Clinical Management of Staphylococcus aureus Bacteremia in Neonates, Children, and Adolescents
Staphylococcus aureus is a common cause of community and health care-associated bacteremia, with authors of recent studies estimating the incidence of S aureus bacteremia (SAB) in high-income countries between 8 and 26 per 100 000 children per year. Despite this, <300 children worldwide have ever been randomly assigned into clinical trials to assess the efficacy of treatment of SAB.
Predicting the causative pathogen among children with osteomyelitis using Bayesian networks – improving antibiotic selection in clinical practice
We have demonstrated the potential use of Bayesian Networks in improving antibiotic selection for children with osteomyelitis
Assessing the burden of laboratory-confirmed respiratory syncytial virus infection in a population cohort of Australian children through record linkage
Respiratory syncytial virus is pervasive across multiple severity levels and diagnoses. Vaccines targeting children <3 months must be prioritized
Causes and Clinical Features of Childhood Encephalitis: A Multicenter, Prospective Cohort Study
Epidemic viral infections predominated as causes of childhood encephalitis in Australia. The leading causes include vaccine-preventable diseases
Progress towards a coordinated, national paediatric antimicrobial resistance surveillance programme
These data support that children are not just 'little adults' in the AMR era, and analyses by age group are important to detect differences in antibiotic susceptibility
Comparative Postmarket Safety Profile of Adjuvanted and High-Dose Influenza Vaccines in Individuals 65 Years or Older
The findings of this postmarketing assessment of the safety of 2 new enhanced influenza vaccines support confidence in ongoing vaccine use
Clinical description and outcomes of Australian children with invasive group a streptococcal disease
Invasive group A streptococcal infection in Australian children is frequently severe and has a high long-term morbidity burden
Immunogenicity of the inactivated influenza vaccine in children who have undergone allogeneic haematopoietic stem cell transplant
This study provides evidence to support annual inactivated influenza vaccine administration to children following allogeneic haematopoietic stem cell transplant
The impact of new universal child influenza programs in Australia: Vaccine coverage, effectiveness and disease epidemiology in hospitalised children in 2018
A significant reduction in severe influenza was observed in Australian children, possibly contributed to by improved vaccine coverage and high vaccine effectiveness
Antibiotic appropriateness and guideline adherence in hospitalized children: results of a nationwide study
Inappropriate antimicrobial prescribing in children was linked to specific risk factors, presenting opportunities for targeted interventions to improve prescribing
Spotting sporotrichosis skin infection: The first Australian paediatric case series
These data highlight the importance of recognising Sporotrichosis in children outside an outbreak setting
A Rationale for Change: An Increase in Invasive Pneumococcal Disease in Fully Vaccinated Children
A review of cases informed a change from a "3 + 0" infant schedule to a "2 + 1" schedule
The Use of Test-negative Controls to Monitor Vaccine Effectiveness: A Systematic Review of Methodology
Our review highlights similarities and differences in the application of the test-negative design that deserve further examination
Invasive group A Streptococcus disease in Australian children: 2016 to 2018 - a descriptive cohort study
Our aims were to describe the epidemiological distribution of paediatric invasive group A Streptococcus disease in Australia and correlate this with influenza notifications
AMEND study protocol: A case-control study to assess the long-term impact of invasive meningococcal disease in Australian adolescents and young adults
This study aims to address this evidence gap by assessing the clinical, physical, neurocognitive, economic and societal impact of invasive meningococcal disease
Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2018: the Influenza Complications Alert Network (FluCAN)
This report summarises the epidemiology of hospitalisations with laboratory-confirmed influenza during the 2018 influenza season
Effectiveness of pneumococcal conjugate vaccine against hospital admissions for pneumonia in Australian children
Reductions in pneumonia-coded hospital admissions in unvaccinated children predominated in non-Aboriginal children with low incidence of pneumonia
Invasive fungal infections in children with acute lymphoblastic leukaemia: Results from four Australian centres, 2003-2013
Invasive fungal infections are more common in children with high-risk acute lymphoblastic leukaemia and in relapsed disease
Attitudes about and access to influenza vaccination experienced by parents of children hospitalised for influenza in Australia
Improving parents’ and providers’ knowledge and confidence in influenza vaccination safety, efficacy, and benefits should be prioritised
Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2017: the Influenza Complications Alert Network (FluCAN)
This report summarises the epidemiology of hospitalisations with laboratory-confirmed influenza during the 2017 influenza season
Timeliness and factors associated with rotavirus vaccine uptake among Australian Aboriginal and non-Aboriginal children: A record linkage cohort study
Aboriginal children are at greater risk of rotavirus disease than non-Aboriginal children and delayed vaccine receipt is substantially higher
Perinatal risk factors associated with skin infection hospitalisation in Western Australian Aboriginal and Non-Aboriginal children
We have quantified the relative influence of perinatal risk factors associated with skin infection hospitalisations in WA children
Links2HealthierBubs' cohort study: Protocol for a study on the safety, uptake and effectiveness of influenza and pertussis vaccines among pregnant Australian women
Multi-jurisdictional cohort of mother-infant pairs to measure the uptake, safety and effectiveness of antenatal IIV and dTpa vaccines in three Australian jurisdictions
Infectious diseases clinician's variation in the management of pediatric Staphylococcus aureus bacteraemia and equipoise for clinical trials
Large variation in antibiotic prescribing amongst clinicians is demonstrated and increased, corresponding with escalating case complexity and persisting MRSA bacteraemia
Temporal trends and socioeconomic differences in acute respiratory infection hospitalisations in children: an intercountry comparison of birth cohort studies
Admissions for ARI were higher in Western Australia and displayed greater socioeconomic disparities than England and Scotland, where ARI rates are increasing
Australian Aboriginal children have higher hospitalization rates for otitis media but lower surgical procedures than non-Aboriginal children
Aboriginal children and children from lower socio-economic backgrounds were over-represented with OM-related hospitalizations but had fewer TTIs
Combination of clinical symptoms and blood biomarkers can improve discrimination between bacterial or viral community-acquired pneumonia in children
Combining elevated CRP with the presence or absence of clinical signs/ symptoms differentiates definite bacterial from presumed viral pneumonia better than CRP alone
Epidemiology of invasive fungal infections in immunocompromised children; an Australian national 10-year review
Non-Aspergillus molds and non-albicans Candida contributed substantially to pediatric invasive fungal infection in our study
Pre-exposure prophylaxis for HIV prevention during pregnancy and lactation: forget not the women and children
The framework for appropriately identifying and managing at-risk pregnant and lactating women requiring PrEP is poorly defined
Caregiver’s attitudes, beliefs, and experiences for influenza vaccination in Australian children with medical comorbidities
Influenza vaccination recommendation by children’s hospital physicians and previous vaccine receipt in hospital was associated with vaccine uptake
Influenza Epidemiology, Vaccine Coverage and Vaccine Effectiveness in Children Admitted to Sentinel Australian Hospitals in 2017
Significant influenza-associated morbidity was observed in 2017 in Australia. Vaccine coverage and antiviral use was inadequate.
The contribution of viruses and bacteria to community-acquired pneumonia in vaccinated children: A case - Control study
Respiratory viruses, particularly respiratory syncytial virus and human metapneumovirus, are major contributors to pneumonia in Australian children
Antibiotic Allergy Labels in Children Are Associated with Adverse Clinical Outcomes
This is the first study demonstrating the negative impact of antibiotic allergy labels on clinical outcomes in children
Geographical disparities in emergency department presentations for acute respiratory infections and risk factors for presenting
One in four ED presentations in WA children are for ARIs, representing a significant out-of-hospital burden with some evidence of geographical disparity
Perinatal Risk Factors Associated With Gastroenteritis Hospitalizations in Aboriginal and Non-Aboriginal Children in Western Australia (2000-2012)
Given the beneficial effect of infant rotavirus vaccination efforts should be taken to optimize rotavirus vaccine coverage in those at highest risk
Adjunctive protein synthesis inhibitor antibiotics for toxin suppression in Staphylococcus aureus infections: a systematic appraisal
A summary of the literature regarding the use of adjunctive protein synthesis inhibitors for toxin suppression in the setting of S. aureus infections is presented
The impact of influenza infection on young children, their family and the health care system
Influenza infection in young children has a significant impact on medication use, absenteeism and the use of health care service
Moraxella catarrhalis Restriction-Modification Systems Are Associated with Phylogenetic Lineage and Disease
We observed an association between Type III DNA methyltransferase presence and Otitis Media-associated middle ear isolates
Active surveillance of 2017 seasonal influenza vaccine safety: An observational cohort study of individuals aged 6 months and older in Australia
AusVaxSafety surveillance demonstrated comparable and expected safety outcomes for the 2017 quadrivalent inactivated influenza vaccine brands used in Australia
Infection characteristics and treatment of Staphylococcus aureus bacteraemia at a tertiary children's hospital
There is a wide spectrum of disease severity in paediatric Staphylococcus aureus bacteraemia
Assessment of on-time vaccination coverage in population subgroups: A record linkage cohort study
On-time coverage of the 2-4-6 month schedule is only 50-60% across specific population subgroups representing a significant avoidable public health risk
Optimising the use of linked administrative data for infectious diseases research in Australia
Increased collaboration and engagement across all sectors can optimise the use of linked data to help reduce the burden of infectious diseases
Determining the pneumococcal conjugate vaccine coverage required for indirect protection against vaccine-type pneumococcal carriage in low and middle-income countries
We will investigate the relationship between PCV coverage and VT carriage among undervaccinated children in Asia and the Pacific
Mucormycosis in Children: Review and Recommendations for Management
we summarize the literature on the epidemiology and diagnosis of this invasive fungal infection and provide suggestions on the management of mucormycosis in children
Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia
Our population-based cohort study demonstrates that >90% coverage in the first year of a universal 3 + 0 PCV program provided high population-level protection
Role of viral and bacterial pathogens in causing pneumonia among Western Australian children: A case-control study protocol
We aim to determine the contribute of bacteria and virus to childhood CAP to inform further development of effective strategies.
The Impact of Pneumococcal Vaccination on Bacterial and Viral Pneumonia in Western Australian Children: Record Linkage Cohort Study of 469589 Births, 1996-2012
We assessed the impact of PCV on all-cause and pathogen-specific pneumonia hospitalizations in Western Australian (WA) children aged 16 years.
Role of viral and bacterial pathogens in causing pneumonia among Western Australian children: A case-control study protocol
Pneumonia is the leading cause of childhood morbidity and mortality globally.
Multidrug-resistant tuberculosis in Australia, 1998-2012
Multidrug-resistant tuberculosis is uncommon in Australia
Macrolides in children with community-acquired pneumonia: Panacea or placebo?
Pneumonia, most often caused by a respiratory virus, is common in childhood.
A microbiome case-control study of recurrent acute otitis media identified potentially protective bacterial genera
We characterised the nasopharyngeal microbiome of these children in comparison to children with rAOM to identify potentially protective bacteria.
Plasmacytoid dendritic cells protect from viral bronchiolitis and asthma through semaphorin 4a-mediated T reg expansion
We found transient pDC depletion during Pneumovirus infection alone predisposed to severe bronchiolitis in early life and subsequent asthma after reinfection.
Dedicated paediatric Outpatient Parenteral Antimicrobial Therapy medical support: a pre-post observational study
We examined the impact of introducing a dedicated team to OPAT, to define the role of increased medical oversight in improving patient outcomes in this cohort.
Advances in Vaccines to Prevent Viral Respiratory Illnesses in Children
Childhood vaccination has played a critical role in the reduction of morbidity and mortality from communicable diseases, including specific respiratory pathogens
Hospital admissions for skin infections among Western Australian children and adolescents from 1996 to 2012
Skin infections are a significant cause of severe disease, requiring hospitalization in Western Australian children, particularly with Aboriginal children
Immunogenicity and safety of single-dose, 13-valent pneumococcal conjugate vaccine in pediatric and adolescent oncology patients
All children who are receiving therapy for cancer should receive a single dose of PCV13 as soon as possible after diagnosis, regardless of prior PCV exposure.
Influenza-Associated Encephalitis/Encephalopathy Identified by the Australian Childhood Encephalitis Study 2013-2015
We aimed to describe case of Influenza associated encephalitis/encephalopathy identified by the Australian Childhood Encephalitis study
Record linkage study of the pathogen-specific burden of respiratory viruses in children
Reliance on hospital discharge diagnosis codes alone will likely underestimate the burden of respiratory viruses
Hospital admissions for skin infections among Western Australian children and adolescents from 1996 to 2012
The objective of this study was to describe the occurrence of skin infection associated hospitalizations in children born in Western Australia (WA).
Potential impact of a maternal vaccine for RSV: A mathematical modelling study
Respiratory syncytial virus is a major cause of respiratory morbidity and one of the main causes of hospitalisation in young children.
A 15-Year Old Burmese Girl With Hemoptysis: A Case Report
A 15 year old girl, born in Hakha, Myanmar, presented with 2 months of intermittent hemoptysis 3 years after immigrating to Australia, via Malaysia.
Dedicated paediatric Outpatient Parenteral Antimicrobial Therapy medical support: a pre-post observational study
The introduction of a formal medical team to Hospital in the Home (HiTH) demonstrated a positive clinical impact on Parenteral Antimicrobial Therapy (OPAT) patients' outcomes.
The Spectrum and Burden of Influenza-Associated Neurological Disease in Children: Combined Encephalitis and Influenza Sentinel Site Surveillance from Australia, 2013-2015
Seasonal influenza is an important cause of acute neurological disease in Australian children.
Using record linkage to validate notification and laboratory data for a more accurate assessment of notifiable infectious diseases
Studies investigating pathogen-specific infectious disease would benefit from using multiple data sources.
Repeated vaccination does not appear to impact upon influenza vaccine effectiveness against hospitalization with confirmed influenza
These findings reinforce current recommendations for annual influenza vaccination, particularly those at greatest risk of influenza disease.
Using record linkage to examine testing patterns for respiratory viruses among children born in Western Australia
Using linked data, we describe changes in respiratory virus testing among children born in Western Australia in 1996-2012
Childhood pneumonia and meningitis in the Eastern Highlands Province, Papua New Guinea in the era of conjugate vaccines: study methods and challenges
Recruitment of large numbers of pediatric pneumonia and meningitis cases and community controls in a third-world setting presents unique challenges
An observational study of febrile seizures: The importance of viral infection and immunization
Determine the frequency of detection of specific viral pathogens in children with febrile seizures
Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2015: the Influenza Complications Alert Network
This report summarises the epidemiology of hospitalisations with laboratory-confirmed influenza during the 2015 influenza season
Influenza C infections in Western Australia and Victoria from 2008 to 2014
Comparison of Influenza C viruses detected from Australian clinical samples with Influenza C viruses detected in other parts of the world in recent years
Epidemiology and mortality of staphylococcus aureus Bacteremia in Australian and New Zealand children
Describe the epidemiology of Staphylococcus aureus bacteremia in children and adolescents younger than 18 years from Australia and New Zealand
Antibiotic duration and timing of the switch from intravenous to oral route for bacterial infections in children: systematic review and guidelines
Systematic review of antibiotic duration and timing of intravenous to oral switch for paediatric infectious diseases and evidence-graded recommendations
Influenza epidemiology, vaccine coverage and vaccine effectiveness in children admitted to sentinel Australian hospitals in 2014
The Influenza Complications Alert Network (FluCAN) is a sentinel hospital-based surveillance programme operating in all states and territories in Australia
Influenza vaccine effectiveness and uptake in children at risk of severe disease
Participation in the preschool influenza vaccination program remains low with parents unconvinced of the benefits and safety of influenza vaccine
Immunogenicity and clinical effectiveness of the trivalent inactivated influenza vaccine in immunocompromised children undergoing treatment for cancer
The trivalent inactivated influenza vaccine is safe, immunogenic, provides clinical protection and should be administered annually to immunosuppressed children receiving treatment for cancer
The relationship between Bordetella pertussis genotype and clinical severity in Australian children with pertussis
In children, we found no relationship between Prn status and markers of severe pertussis
A prospective cohort study assessing the reactogenicity of pertussis and influenza vaccines administered during pregnancy
Data on systemic and local reactions following receipt of TIV and dTpa during pregnancy support the safety of antenatal vaccination
Systematic review and meta-analysis of respiratory viral coinfections in children
Coinfection is not associated with increased clinical severity, but further investigations by pathogen pairs are warranted
Optimization is required when using linked hospital and laboratory data to investigate respiratory infections
Chart review to validate linked microbiological data
Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation
Evidence-based recommendations for the antifungal management of common, rare and emerging mould infections in both adult and paediatric populations
Introduction to the updated Australian and New Zealand consensus guidelines for the use of antifungal agents in the haematology/oncology setting, 2014
This article introduces the second revision of the Australian and New Zealand consensus guidelines for the use of antifungal agents in the haematology/oncology setting.
The safety of seasonal influenza vaccines in Australian children in 2013
Our objective was to examine influenza vaccine safety in Australian children aged under 10 years in 2013.
What do infectious diseases physicians do? A 2-week snapshot of inpatient consultative activities across Australia, New Zealand and Singapore
We performed a 2-week prospective survey of formal ID physician activities related to direct inpatient care, encompassing 53 hospitals throughout Australia,...
Modelling the seasonal epidemics of respiratory syncytial virus in young children
This paper describes a mathematical model used to predict when an epidemic of respiratory syncytial virus (RSV) will occur so that preventive measures, such...
Pandemic clinical case definitions are non-specific
During the early phases of the 2009 pandemic, subjects with influenza-like illness only had laboratory testing specific for the new A(H1N1)pdm09 virus.
The impact of pandemic A(H1N1)pdm09 influenza and vaccine-associated adverse events on parental attitudes and influenza vaccine uptake in young children
This paper reports on the shift in parental attitude to vaccination after 2010, due to an unprecedented increase in febrile reactions in children receiving...
Effectiveness of trivalent flu vaccine in healthy young children
This paper reports some of the findings from the Western Australian Influenza Vaccine Effectiveness Study, commenced in 2008, to evaluate a program providing...
Multidrug-resistant tuberculosis in Western Australia, 1998-2012
Our objective was to describe the epidemiology, clinical features, health care resource use, treatment and outcomes of multidrug-resistant tuberculosis...
International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines.
The global spread of the 2009 novel pandemic influenza A (H1N1) virus led to the accelerated production and distribution of monovalent 2009 Influenza A...
Clinical Predictors of Influenza in Young Children: The Limitations of “Influenza-Like Illness”
This study aims to identify clinical predictors of influenza infection in children ≤5 years old from which age-specific ILI definitions are then constructed.
How Accurate Are International Classification of Diseases-10 Diagnosis Codes in Detecting Influenza and Pertussis Hospitalizations in Children?
Influenza diagnosis codes had high specificity (98.6%) and modest positive predictive value (PPV; 84.1%) and sensitivity (86.1%) for a laboratory-confirmed...
Bacillus Cereus Bacteremia and Multiple Brain Abscesses During Acute Lymphoblastic Leukemia Induction Therapy
Bacillus cereus can cause serious infections in immunosuppressed patients. This population may be susceptible to B. cereus pneumonia, bacteremia, cellulitis,...
Safety surveillance of influenza vaccine in pregnant women
Vaccination is the most effective strategy for preventing influenza infection in pregnancy.
Idiosyncratic nature of voriconazole photosensitivity in children undergoing cancer therapy
In adults, the unpredictability of voriconazole pharmacokinetics, particularly in those patients receiving chemotherapy, is well recognised. A paucity of...
Use of data linkage to investigate the aetiology of acute lower respiratory infection hospitalisations in children
The aim was to document the aetiology of acute lower respiratory infection (ALRI) hospitalisations in Western Australian children
Trivalent influenza vaccine and febrile adverse events in australia, 2010: Clinical features and potential mechanisms
Increased numbers of children presenting with febrile adverse events following trivalent influenza vaccine (TIV) were noted in Australia in 2010.
Clinical associations and prevalence of Scedosporium spp. in Australian cystic fibrosis patients: identification of novel risk factors
Risk factors for the association of Scedosporium in cases of cystic fibrosis (CF) and its clinical implications are poorly understood
Detection of the rapid emergency of the H274 mutation associated with oseltamivir-resistance
In 2009 a new swine-origin influenza virus A/H1N1 (A/H1N1 09) emerged, causing the century's first pandemic.
Complexity of Influenza Outbreaks during the World Youth Day 2008 Mass Gathering and its Impact on Community Seasonal Influenza Activity
How Influenza outbreaks during mass gatherings have been rarely described, and detailed virologic assessment is lacking.
Skull base osteomyelitis: Fungal versus Bacterial Infection
An 18-year (1990-2007) retrospective review of patients with Skull-base osteomyelitis (SBO) presenting to Westmead Hospital was performed.
Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections
This review aims to systematically identify and summarise the effects of different antifungal therapies in children with proven, probable or suspected...
Detection of occult Scedosporium species in respiratory tract specimens in cystic fibrosis (CF) by use of selective media
Respiratory samples from cystic fibrosis outpatients were cultured on Sabouraud's dextrose agar (SABD) containing antibiotics, Mycosel, and Scedosporium-sel...
Comparison of a rapid antigen test with nucleic acid testing during cocirculation of pandemic influenza A/H1N1 09 and Seasonal influena A/H3N2
The rapid diagnosis of influenza is critical in optimizing clinical management. Rapid antigen tests have decreased sensitivity in detecting pandemic influenza.
Publications
Current and Previous Competitive Grant Support
Russell F, Mulholland K, Satzke C, Dunne E, La Vincete S, Newton P, Xeuatvongsa A, Dance D, Phetsouvanh R, Blyth C, Pomat W, Lehmann D, Ford R, Duke T, Richmond P, Mungun T, Narangerel D, Surenkhand G, Fox K, Hinds J. To demonstrate how nasopharyngeal surveillance in hospitalized children with respiratory illness or pneumonia can be used to estimate the pneumococcal conjugate vaccine coverage required to show evidence of herd immunity, and monitor the vaccine's impact on carriage, and provide information for national planners to maximize the effectiveness of their immunization program. Bill and Melinda Gates Foundation Global Development Program (OPP1115490), $2,994,783
Silva D, Prescott S, Beaman M, Blyth C, Carapetis J, Carter K, et al, 'Body Composition PEA POD', NHMRC Equipment Grants.
Kirkham L, Richmond P, Thornton R, Prescott S, Strunk T, Waddington C, Blyth C, Stick S, Kikic A, Currie A, Hales B, Le Souef P. Bio-Plex® 200 suspension array system. NHMRC equipment grants (RA/1/466/204) $50,000
Giddings H, Moore H, McIntyre P, de Klerk N, Liu B, Blyth C, Snelling T. Vaccination timeliness in Aboriginal and non-Aboriginal infants: risk factors for delayed vaccination and impact on disease burden-a record linkage study National Health and Medical Research Council Project Grants 2014 (APP1082342), A$520,742
Moore H, Hardelid P, Blyth C, Pebody R, Gilbert R. Using unique data linkage infrastructure to conduct international comparisons of acute respiratory infections in children. UWA Research Collaboration Awards 2014. A$18,437
Blyth C, Snelling T, Smith D. PneumoWA: A case-control study of the role of viral and bacterial pathogens in causing pneumonia among Western Australian children. Telethon-Perth Children's Hospital Research Fund 2013. A$198,506
Waddington C, Snelling T, Borland M, Martin A, Blyth C. A randomised control trial of nitazoxanide for the treatment of bronchiolitis in infants. Telethon-Perth Children's Hospital Research Fund 2013. A$217,522
Manley E, Blyth C, Richond P, Keil T, King B. Pneumococcal meningitis in Western Australian children 1990-2013: Assessing the impact of vaccination on epidemiology, clinical course, microbiology, resource use and outcome. PMH Foundation Seeding Grant 2013. A$8621
Blyth C, Richmond P, Smith D, Effler P. Preventing influenza morbidity and mortality in West Australian children through vaccination. Telethon-Perth Children's Hospital Research Fund 2012. A$153,000
Peacock C, Blyth C, Jamieson S, Perkins T, Thornton R, Coates H Defining a protective microbiome in otitis media and identification of potential probiotics. Telethon-New Children's Hospital Research Fund 2012. A$180,000
Snelling T, Goff Z, Weatherall R, Blyth C. Determining the impact and cost-effectiveness of an Antimicrobial Stewardship Program in an Australian paediatric hospital. State Health Research Advisory Council Research Translation Projects. A$178,000
Snelling T, Waddington C, Blyth C, Riley T, Moore H, Lehmann D. The pathogen-specific burden of enteric and blood stream infections in children and young people in Western Australia. Princess Margaret Hospital Foundation New Investigator Project Grants 2013. A$79,473
Dunne E, Satske C, Blyth C, Pomat W, Lehmann D, Mulholland K. Pneumococcal gene expression in carriage and disease. MCRI Infection and Immunity Theme Research Investment Funding. A$15,000
Ford R, Pomat W, Horward P, Aho C, Michael A, Vallely L, Greenhil A, Blyth C, Lehmann D. The Risk Factors Involved with Acute Lower Respiratory Infections and Meningitis in Papua New Guinean Children. PNGIMR ICRAS grant 2013. PNG K315,000
Moore HC, Blyth CC. INTEGRATE, IDENTIFY, INTERVENE: Identifying opportunities for preventing respiratory infections in children through integrating population-based health, laboratoryand immunisation data: National Health and Medical Research Council Project Grants 2012 (APP1045668): A$428,469
Morley SC, Utterson E, Todd E, Blyth C, Burnham CA, Druley T, Lehmann D, Pomat W, Shaw W. Defining Host Determinants of Severe Childhood Pneumococcal Pneumonia. Children's Discovery Institute Grant, St. Louis Children's Hospital and Washington University: US$150,000
Giddings HF, Moore HC, McIntyre P, Blyth C, Liu B, Richmond P, de Klerk N, Jorn L. Linkage of the Australian Childhood Immunisation Register (ACIR) and state-based registers to evaluate and inform Australia's immunisation program. Population Health Research Network Proof of Concept Collaboration #4 Grant. A$157,457
Hung T-Y, Cole C, Blyth C. Immunogenicity and safety of a 13-valent Pneumococcal Conjugate vaccine in paediatric oncology patients. Princess Margaret Hospital Seeding Grants 2012: A$20,000
Blyth C. Children's Antimicrobial Management Program (ChAMP). Clinical Integration and Innovation Grant 2011, Department of Health, Western Australia: A$872,336
Blyth C, Greenhill A, Kirkham LA, Lehmann D, Duke T, Tanumei J, Hwaihwanje I. The Aetiology of Acute Lower Respiratory Tract Infection and Meningitis in Hospitalised Children from the Eastern Highlands Province, Papua New Guinea. Pfizer Investigator Initiated Research Grant 2011: A$249,540
Chen S, Ananda-Rajah M, Arthur I, Blyth C, Chambers S, Ellis D, Gottlieb T, Hale K, Halliday C, Kidd S, McCormack M, Marriott D, Meyer W, Morrissey O, Playford G, Shaw D, Slavin M, Sorrell T, Thursky K, van Hal S. Case registry of non-Aspergillus mould infections: epidemiology, risk factors, disease syndromes and outcomes. Pfizer Australia and Gilead Science, Australia 2010: A$127,600
Iredell J, Blyth C, Branley J, Dwyer DE, Kesson A, Paterson D, van Hal SJ, Webb S. The contribution of Co-infection on Outcomes in Severe Influenza during 2009. Merck, Sharpe & Dohme (MSD) 2009: A$123,400